l opioid receptors (lORs) are expressed by a variety of cell types, i.e., neurons and immunocytes, and are known to mediate immune response, in addition to analgesia and gastrointestinal functions, including motility, secretion, electrolyte balance, and absorption.
INTRODUCTION
l opioid receptors (lORs) are G-protein coupled receptors that are activated by endogenous opioid peptides and structurally distinct alkaloids, drugs commonly used for pain control.
1,2 lORs are abundantly expressed in the central nervous system, 3, 4 where they mediate analgesia and addiction, 5, 6 and the enteric nervous system, [7] [8] [9] where they mediate gastrointestinal (GI) motility, secretion, and electrolyte and fluid transport. [10] [11] [12] lORs and their ligands are also localized to different types of immune cells such as neutrophils, macrophages, and T and B cells throughout the body, including the GI tract. 9, [13] [14] [15] Furthermore, immune cells secrete endogenous opioids and mediate inflammatory responses by direct interaction with opioid receptors. [16] [17] [18] The widespread distribution of lORs parallels the broad spectrum of biological functions mediated by these receptors when activated by endogenous opioid peptides and opioid drugs in the central nervous system and periphery, including immune responses. 5, 6, 11, 12, 15, 17, 19 There is increasing evidence that lORs play a protective role in different inflammatory conditions of the digestive system. Upregulation of lOR mRNA has been reported in different animal models of intestinal inflammation 20, 21 and in patients with inflammatory bowel disease (IBD), 22 whereas lOR mRNA expression was impaired in chronic hepatitis. 23 Furthermore, activation of lORs with selective agonists has been shown to protect from intestinal inflammation induced by ischemia/reperfusion, 24 prevent acute hepatitis 23 and ameliorate acute experimental colitis induced by intrarectal 2,4,6-trinitrobenzebesulfonic acid (TNBS). 20 The above findings provided the background for the current study, which was designed to test the effect of lOR activation on colitis induced by dextran sodium sulfate (DSS), a well-established, chemically induced model of colitis that is strongly dependent on innate immune response 25 during the acute and delayed phase of inflammation. We first determined whether lOR expression correlates with clinical symptoms and local and systemic inflammatory indexes, including inflammatory cell infiltration, and cytokines levels. To determine the mechanisms underlying the effect of lOR activation on inflammation, in addition to the inflammatory indexes, we evaluated the tissue expression of Bcl-xL, an antiapoptotic member of the Bcl-2 family of apoptosis regulator proteins, which protects from injury-induced cell death, [26] [27] [28] apoptosis, and the transcription nuclear factor-kB (NF-kB), which potentiates inflammatory and immune responses by inducing cytokines production. 29, 30 This study suggests that activation of peripheral lORs ameliorates inflammation in acute experimental colitis by reducing cytokine production, cellular infiltration, tissue damage, and apoptosis through the suppression of NF-kB and the upregulation of Bcl-xL, but does not have any detectable effect during the delayed phase of inflammation.
MATERIALS AND METHODS
Experiments were performed on adult C57BL/6J mice (20-25 g; Charles River Laboratory International, Inc, Hollister, CA, USA) housed in rooms with controlled temperature and light-dark cycles. Mice had unrestricted access to standard mouse chow and tap water, and acclimated for 1 week before experimentation. Animal care and procedures were in accordance with the National Institutes of Health recommendations for the humane use of animals. Experimental procedures were reviewed and approved by the Animal Research Committee of the University of California, Los Angeles. All efforts were made to minimize the number of animals used and their suffering. Animals were closely monitored by the Veterinarian, and the animal welfare was assessed to assure they did not develop signs of discomfort, which would have warranted interruption of treatment and/or euthanasia. 31 in addition to DAMGO. All CTAP doses induced significant inhibition of DAMGO-induced effects, but the 2.0 mg had less variability, therefore it was selected for subsequent studies. The effects of systemically administered DAMGO are due to the activation of peripheral lORs, as DAMGO does not readily pass the blood-brain barrier. 32 CTAP passes the blood-brain barrier, 33 but it does not block the effect of systemic DAMGO on lORs when it is administered intracerebroventricularly. 32 To determine the role of Bcl-xL on DAMGO effect in experimental colitis, a set of mice that received DSS in drinking water was treated with ABT 737 (40 mg/kg daily; Selleck Chemicals, Houston, TX, USA), 34 a selective inhibitor of the Bcl-2 family, including Bcl-xL, in the presence or absence of DAMGO.
Induction of colitis
Another set of mice (total 30) received a single cycle of DSS treatment (3% in drinking water ad libitum for 5 days as above) followed by 4 weeks of drinking water only, or a single cycle of 3% DSS with DAMGO, 0.02 mg/kg a day starting at day 2 of DSS administration and continuing after the end of DSS for 2 or 3 weeks, and then water to the end of the 4 weeks. With this paradigm, C57BL/6J mice euthanized 4 weeks following the end of a single cycle of DSS showed active colitis. 35 Mice were weighed daily and visually inspected for diarrhea and rectal bleeding. Mice were euthanized at the end of each experimental procedure (either at the end of 5 days DSS treatment or at 4 weeks following the end of DSS treatment) with an overdose of Isoflurane for tissue collection. Colon from the coloncecal junction to the anus was removed from each animal and flushed with cold phosphate-buffered saline. Tissue obtained from each colon was processed for histology, Western blot, MPO activity, and quantitative RT-PCR (qRT-PCR).
Disease activity index
Clinical assessment of inflammation included daily monitoring of bodyweight, stool consistency, and fecal blood. The DAI was calculated according to a modified protocol 36 by grading loss of weight on a scale of 0 to 4 (0 = normal; 1 = 0-5%; 2 = 5-10%; 3 = 10-20%; 4 = >20%), stool consistency on a scale of 0 to 2 (0 = normal; 1 = loose stools; 2 = diarrhea), and presence of fecal blood on a scale of 0 to 2 (0 = normal; 1 = bleeding; 2 = severe bleeding). The final DAI value for each animal was expressed as the average of the combined scores.
Myeloperoxidase activity
Myeloperoxidase activity, an index of tissue neutrophil infiltration, was measured in the colon as previously described. 24 Briefly, 
Histological damage
For the evaluation of the microscopic histological damage, colon specimens were fixed in 10% formalin/phosphate buffer saline overnight, embedded in paraffin and sectioned. Tissue sections (4 lm) were stained with hematoxylin and eosin. Microscopic histological damage score was evaluated by a person unaware of the treatments and was based on a semiquantitative scoring system 24, 37 in which the following features were graded: damage of epithelium (0 = morphologically normal; 1 = zonal destruction of the epithelial surface; 2 = diffuse epithelial destruction and/or mucosal ulcerations involving submucosa; 3 = severe epithelial destruction), inflammatory cell infiltration (0 = absence of infiltrate or fewer than five cells; 1 = mild infiltration to the lamina propria; 2 = moderate infiltration to the muscularis mucosae; 3 = high infiltration to the muscularis mucosae; 4 = severe infiltration involving the submucosa), separation of muscle layer and muscularis mucosae (0 = normal; 1 = moderate; 2 = severe), and goblet cells depletion (0 = no depletion; 1 = presence of nonorganized goblet cells; 2 = presence of 1 to 3 areas without goblet cells; 3 = more than 3 areas without goblet cells; 4 = complete depletion of goblet cells). The total score of individual mice was expressed as the average of the sum of the different histological subscores.
Cytokines and lOR mRNA expression in the colon: real-time quantitative RT-PCR We selected RT-qPCR as a measure of cytokine expression to compare the effect of lOR activation on DSS-induced colitis to the effects on TNBS-induced colitis 20 and intestinal ischemia/ reperfusion. 24 Samples of colon were homogenized and total RNA was extracted using the Absolutely RNA RT-PCR Miniprep Kit (Stratagene, La Jolla, CA, USA). The purity and amount of the purified RNA was determined by spectrophotometry (Nanodrop 1000; Thermo Scientific, Waltham, MA, USA). The NanoDrop measured the quantity and quality of a 1 lL sample of extracted RNA on the basis of the optical density 260 and optical density ratio 260/280, respectively. Only the RNA with an optical density 260/280 ratio greater than 1.8 was used for RT-PCR gene expression analysis. The integrity of the total RNA was assessed by electrophoresis on a denaturing agarose gel stained with GelRed TM , in which the 18S and 28S ribosomal RNA bands were inspected. The expression of lOR and cytokines, tumor necrosis factor-a (TNF-a) and interleukin (IL)-1b, IL-6, and IL-10 mRNA was assessed by qRT-PCR using TaqMan Gene Expression Master Mix and Pre-Developed TaqMan Assay (Applied Biosystems, Foster City, CA, USA) specific to mouse lOR (Mm01188089), TNF-a (Mm99999068_m1), IL-1b (Mm00434228_m1), IL-6 (Mm00446190_m1), IL-10 (Mm01288386_m1), and the housekeeping gene b-actin (Mm1205647_g1). The data were collected using a Stratagene Mx 3000p machine. Expression of b-actin was measured in parallel for every sample, and the data obtained for lOR, TNF-a, IL-1b, IL-6, and IL-10 were normalized to those of the b-actin. Relative quantities (RQ) of mRNA were analyzed using the comparative threshold cycle (Ct) method. 38, 39 Western blotting analysis of Bcl-xL, NF-kB, caspase 3, and caspase 7
Whole protein extracts were prepared from mouse frozen colon samples. Tissues were homogenized using PowerGen homogenizer (Fisher Scientific, Torrance, CA, USA) in 1 mL of lysis buffer. After incubation on ice for 30 min, protein extracts were centrifuged for 20 min at 4°C; supernatant fractions were collected and their protein contents were quantified using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Samples were diluted (v/v) in Laemmli sample buffer (pH 6.8) and boiled 10 min before loading onto gel. Homogenates (45 lg) were fractionated using SDS-10% polyacrylamide electrophoresis gel (65 V, overnight) and prestained marker proteins were used as molecular mass standards (Bio-Rad Laboratories, Hercules, CA, USA). Separated proteins were transferred electrophoretically to PVDF Immobilon-FL membranes (Millipore, Temecula, CA, USA). Membranes were blocked 1 h at room temperature in LI-COR Blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) and incubated at 4°C overnight with a rabbit polyclonal anti-Bcl-xL (1:200) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), NF-kB antiserum (Santa Cruz Biotechnology), rabbit anti-cleaved caspase-3 or cleaved caspase 7 (1:1000; Cell Signaling, Danvers, MA ,USA), or a mouse anti-GAPDH antibody (Cell Signaling) that served as housekeeping protein. Cleaved caspase 3 and 7 are the activated caspase forms leading to apoptosis. 40 Blots were washed and incubated 2 h at room temperature with an infrared fluorescent secondary antibody IRDye 680 goat anti-rabbit or IRDye 800 goat anti-mouse (1 : 10 000). Images were collected using the LI-COR Odyssey Infrared Imaging System, and intensities were quantified using the Odyssey Application Software Version 3.0. Bcl-xL, NF-kB and caspase 3 and 7 protein levels were normalized to GAPDH levels.
Statistical analysis
Data were expressed as mean AE SE. Comparison among groups was made by using one-way ANOVA followed by the post hoc Bonferroni test, which corrects for any variance that compares means from unequal sample sizes. Student's t-test was used when comparing only two groups. Differences were considered significant at p < 0.05. Analysis was performed in Prism 5 (GraphPad Software, San Diego, CA, USA).
RESULTS

Induction of colitis and DAI
Mice treated with 3% DSS for 5 days had a significant increase in DAI (p < 0.01) compared to control animals that received tap water, consistent with the development of acute colitis (Fig. 1) . Treatment with DAMGO at 0.02 mg/kg day induced a significant reduction in DAI (p < 0.05). DAMGO at the lowest (0.01 mg/kg) and higher doses (0.04 or 0.08 mg/kg) did not affect DAI (Fig. 1) . Similar data were obtained with MPO (see below), which is consistent with previous studies using different inflammation models. 20, 24 Therefore, we used 0.02 mg/kg day of DAMGO for all subsequent experiments. To demonstrate that the effect of DAMGO was mediated by activation of lOR, we used increasing concentrations of the antagonist CTAP (0.2, 2 or 4 mg/ kg day), which was administered at the same time as DAMGO (0.02 mg/kg). These experiments showed that all the doses of CTAP significantly reversed the effect of DAMGO on DAI (p < 0.05-0.01), but CTAP at the 2 mg/kg had the lowest variability compared to other doses (Fig. 1) .
In the group of mice treated with 1 cycle of DSS and followed up for 4 weeks from the end of the DSS treatment before euthanasia, there was a progressive and significant decrease in bodyweight starting at day 6 to day 19 (p < 0.05-0.001). Bodyweight slowly increased back to initial values at day 21 and continued to increase up to day 34 ( Fig. 2A) . In mice that received 0.02 mg/kg day of DAMGO during DSS administration followed by 0.02 mg/kg day of DAMGO for 2 weeks and then water for 2 more weeks, the loss in bodyweight between days 8 and 10 was significantly less compared to mice that did not receive DAMGO ( Fig. 2A) . Mice also showed a progressive and significant increase in DAI from day 3 to day 19 (p < 0.001) (Fig. 2B) , which was significantly reduced by treatment with DAMGO between days 3 and 6 (Fig. 2B) . The results in animals that received DAMGO for 3 weeks followed by 1 week of water were completely superimposable with the ones obtained with 2 weeks of DAMGO following DSS treatment shown here.
MPO activity
Mice treated with 3% DSS showed a significant increase in intestinal MPO activity (p < 0.001) compared to control (Fig. 3) . DAMGO at 0.02 mg/kg day significantly reduced MPO activity (p < 0.01) (Fig. 3) , and this effect was reversed by the lOR antagonist CTAP. DAMGO at 0.01 mg/kg day did not modify MPO values, whereas higher concentrations of DAM-GO (0.04 and 0.08 mg/kg) reduced the MPO response, but not significantly (Fig. 3) . All concentrations of CTAP reversed the DAMGO effect on MPO (p < 0.05-p < 0.001) (Fig. 3) . CTAP (2 mg/kg) alone did not significantly affect the MPO activity in mice with DSS-induced acute colitis (CTAP+DSS 2.80 AE 0.29 vs DSS 2.50 AE 0.17, n = 4 each group).
In mice euthanized 4 weeks following DSS treatment, MPO activity was still significantly increased compared to control (p < 0.001), though significantly less compared to the acute colitis (p < 0.01) (Fig. 3) . Treatment with DAMGO for 2 or 3 weeks followed by water did not have any effect on MPO activity (Fig. 3 ) compared to mice that only received water for 4 weeks following the DSS cycle.
Intestinal histology
There was significant tissue damage in mice treated with 3% DSS for 5 days (p < 0.001 vs controls), which included pronounced infiltration of inflammatory cells within lamina propria and submucosa, severe edema and lifting of the epithelial layer from the lamina propria (Fig. 4) , crypt abscesses, pronounced depletion of goblet cells, and muscle thickening compared to control (Fig. 4) . Treatment with DAMGO significantly reduced DSS-induced histological damage (p < 0.001 vs DSS; Fig. 4 ). This effect was completely reversed by the co-administration of the lOR antagonist peptide, CTAP (p < 0.05 vs DAMGO treated; Fig. 4) .
Tissue damage was still significant in mice at 4 weeks following DSS treatment compared to controls (p < 0.001), but it was reduced compared to the tissue damage observed in acute colitis (p < 0.01). However, tissue damage in these animals was not affected by either of the DAMGO treatment regimens (Fig. 4) .
Cytokine mRNA expression
The levels of TNF-a, IL-1b, and IL-6 mRNA quantified by qRT-PCR were markedly and significantly increased in the colon of mice with acute colitis compared to control (p < 0.001) (Fig. 5) . Treatment with DAMGO significantly reduced the levels of TNF-a, IL-1b, and IL-6 mRNA compared to animals treated with DSS only (Fig. 5) (p < 0.001) . The levels of IL-10 were very low overall, compared to the other cytokines. There was only a trend, but not significant increase in the expression of IL-10 mRNA in acute DSS colitis (Fig. 5) , which was significantly reduced by DAMGO treatment (p < 0.05). DAMGO effects on cytokine expression were abolished by CTAP (Fig. 5) .
Four weeks after DSS treatment, there was still a significant increase in TNF-a and IL-6 mRNA levels compared to control (p < 0.05-p < 0.01), however the levels of these cytokines were significantly lower compared to the levels in acute colitis (p < 0.01-p < 0.001). On the other hand, the levels of IL-1b and IL-10 were not increased in these mice compared to controls. Treatment with DAMGO for either 2 or 3 weeks after the end of DSS treatment did not affect any of these cytokines levels (Fig. 5) . lOR mRNA expression in DSS-induced colitis Acute colitis induced by 3% DSS for 5 days triggered a significant increase in the levels of lOR mRNA compared to control mice (1.71 AE 0.2 vs 1.07 AE 0.11, n = 8 in each group) (p < 0.001). lOR mRNA levels 4 weeks following DSS treatment (n = 5) were significantly lower than in acute colitis (0.42 AE 0.03 vs 1.71 AE 0.2; p < 0.001), and not significantly different from controls.
Expression of Bcl-xL and NF-kB in DSS-induced colitis
Mice treated with 3% DSS and injected with DAMGO presented a significant increase in Bcl-xL expression (p < 0.001) compared to control mice, effect that was abolished by CTAP administration (p < 0.001) (Fig. 6 ).
CTAP alone did not affect the expression of Bcl-xL in DSS acute colitis (86.52 AE 9.1% in DSS+CTAP vs 103.7 AE 10.14% in DSS alone). By contrast, in mice that were followed up for 4 weeks after DSS treatment, there was no increase in Bcl-xL levels in response to DAMGO (Fig. 6) . DAMGO had no effect on the expression of Bcl-xL in normal mice (data not shown). To verify that the increased level of Bcl-xL in response to DAMGO in acute colitis reflected a decrease in apoptosis, we examined the levels of caspase 3 and 7 as marker of apoptosis. 40 This study showed that both caspase enzymes were significantly increased in DSSinduced colitis, the increased levels were reversed to controls by DAMGO and CTAP antagonized DAMGOinduced suppression of both caspase 3 and 7 (Fig. 7) . In our study, mice treated with 3% DSS showed a significant increase in NF-kB (p < 0.01) compared to A B Figure 2 Time course changes of bodyweight and DAI in DSS-induced colitis. Changes in bodyweight (A) and DAI (B) in mice during and following the induction of colitis. Open circles represent results in mice exposed to 3% DSS for 5 days followed by drinking water alone for 4 weeks (n = 10). Closed circles represent changes in mice treated with 0.02 mg/kg day DAMGO during DSS administration and for 2 weeks following DSS treatment followed by 2 weeks of water (n = 5). (A) There was a significant reduction in bodyweight in DSS treated animals from day 6 to day 19 compared to time 0 ( # p < 0.05, ## p < 0.01, ### p < 0.001); bodyweight progressively returned to the value at time 0 and then increased. Bodyweight loss was significantly reduced by DAMGO treatment between day 8 and 10 (*p < 0.05). (B) Similarly, DAI was significantly increased between days 3 and 19 compared to time 0 ( ### p < 0.001) and was comparable to normal starting at day 26. DAMGO treatment significantly reduced DAI during the acute phase (day 3-6) (*p < 0.05; **p < 0.01) in DSS-treated mice and gradually returned to normal as in animals without DAMGO treatment. Data are expressed as means AE SEM. Animals treated with DAMGO for 3 weeks following DSS and then 1 week of water showed the same results (data not shown). control mice. NF-kB upregulation was prevented by DAMGO treatment (p < 0.001), effect that was reversed by CTAP (p < 0.001) (Fig. 6) . CTAP alone did not affect the expression of NF-kB in DSS acute colitis (256.46 AE 23.76% in DSS + CTAP vs 237.60 AE 23.25% in DSS alone). By contrast, NF-kB was not upregulated in mice 4 weeks following DSS treatment, and remained comparable to control levels with or without DAMGO (Fig. 6) .
Effect of Bcl family inhibitor in acute DSSinduced colitis
This set of experiments investigated the effect of an inhibitor of the Bcl family of enzymes on MPO and NF-kB as markers of inflammation in acute colitis. In mice with DSS-induced acute colitis treated with DAMGO and Bcl inhibitor, the levels of MPO were similar to the levels observed in mice (C) Comparison of the effect of DAMGO at 0.02 mg/kg on MPO in acute (n = 11) and delayed phase (4 weeks following the end of DSS treatment) (n = 9) of colitis. DAMGO administered daily from day 2 to 5 of DSS treatment and for 2 weeks after the end of DSS followed by 2 more weeks of drinking water (n = 9) did not have any effect on MPO compared to mice that only received drinking water following DSS. MPO activity 4 weeks after the end of DSS treatment was significantly higher than in controls (***p < 0.001), but was significantly less compared to acute DSS ( ## p < 0.01). Similarly, DAMGO administered for 3 weeks followed by one more week of water (data not shown) did not have any effect on MPO.
that received DSS without DAMGO treatment, whereas Bcl alone did not affect MPO levels in acute colitis (Fig. 7) . Similarly, the levels of NBFkB in mice with DSS-induced acute colitis treated with DAMGO and Bcl inhibitor were comparable to the levels in DSS alone. Bcl inhibitor alone did not affect the expression of NF-kB in DSS mice (Fig. 7) . 
DISCUSSION
This study shows that DSS-induced acute colitis, characterized by high DAI, pronounced neutrophil infiltration, tissue damage, and increased expression of cytokines and NF-kB, was markedly improved by lOR activation, which significantly reduced inflammatory indexes and decreased the levels of inflammatory cytokines and NF-kB. DAMGO's beneficial effects were associated with upregulation of the antiapoptotic factor, Bcl-xL, were mediated by peripheral lORs, as DAMGO does not readily pass the blood-brain barrier, 32 and were prevented by the selective and potent lOR antagonist, CTAP, 31 which is likely to act directly on DAMGO-activated peripheral lORs, as CTAP administered i.c.v. does not block the effect of systemic DAMGO. 32 Acute colitis also triggered the induction of lOR mRNA. By contrast, 4 weeks following DSS administration, symptoms subsided as indicated by the weight gain and normalization of DAI suggesting remission, independently of the presence or absence of DAMGO treatment. However, inflammatory indexes were still significantly elevated compared to controls, though they were much less pronounced than in the acute phase of colitis, indicating persistence of inflammation. NF-kB was not activated and lOR mRNA was back to normal levels. DAMGOinduced activation of lORs did not affect any of the inflammatory indexes nor did alter Bcl-xL expression. These findings suggest that activation of lOR ameliorates acute colitis by reducing the inflammatory response and cytokine expression through a mechanism involving the upregulation of the antiapoptotic regulator factor, Bcl-xL, and the suppression of the NFkB inflammatory pathway. By contrast, DAMGO does not maintain its beneficial effect during the delayed phase of colitis, which coincided with the absence of DAMGO-induced Bcl-xL upregulation, and was Figure 5 Effect of DAMGO on cytokine levels in DSS colitis. In mice with acute colitis (n = 17), mRNA levels of pro-inflammatory cytokine TNF-a, IL-1b, and IL-6 were significantly higher compared to control (***p < 0.001) (n = 9), whereas IL-10 was only slightly, but not significantly, elevated. DAMGO (0.02 mg/kg s.c.) treatment (n = 10) significantly reduced TNF-a, IL-1b, IL-6 ( ### p < 0.001) and IL-10 ( # p < 0.05) mRNA expression compared to DSS only. DAMGO inhibitory effect on TNF-a, IL-1b, IL-6 mRNA levels was reversed by CTAP (n = 6) ( & p < 0.05, && p < 0.01 vs DAMGO). Mice at 4 weeks after DSS treatment (n = 5) showed a significant increase in TNF-a and IL-6 expression compared to control (*p < 0.05, **p < 0.01); however, all cytokines were significantly lower at 4 weeks compared to acute colitis ( # p < 0.05, ## p < 0.01, ### p < 0.001). DAMGO (n = 5) did not affect cytokine mRNA levels at 4 weeks following DSS. All values are expressed as mean AE SEM.
characterized by normal levels of NF-kB and lOR mRNA. The normalization of NF-kB expression and lOR mRNA levels, and the reduction in inflammatory indexes and cytokines following DAMGO treatment during the acute phase of colitis might play a role in the reduced level of inflammation observed in delayed colitis. Whether the reduced acute inflammation resulting from lOR activation influences the inability of DAMGO to further affect the inflammatory responses in the delayed phase of experimental colitis remains to be elucidated.
The reduction in pro-inflammatory cytokines such as TNFa, IL-1b, and IL-6 in response to lOR activation observed in our model of acute colitis is consistent with the reported inhibitory effect of lOR agonists on cytokines in a different experimental model of colitis, and with the cytokine increased expression in animals with genetic deletion of lOR gene. 20 DAMGO also reversed the slight, not significant increase in IL-10 expression induced by DSS. IL-10 is a cytokine produced by T-helper2 cells, which has been regarded as a downregulator of inflammatory response and an inhibitor of pro-inflammatory cytokine production. 41 However, other studies do not confirm the protective effect of IL-10 in inflammation. 42 The role of this cytokine in this model of acute colitis highly dependent on the innate immune response remains to be established. Interestingly, in addition to regulate immune response, lORs are also modulated by cytokines, supporting the concept of a bidirectional interaction and regulation between the lORs and the immune system. 43, 44 The upregulation of lOR mRNA in our model of acute colitis extend previous findings in other models of intestinal inflammation 20, 21 and is consistent with studies in humans showing increased expression of lOR mRNA in colonic specimens of patients with active IBD compared to inactive disease. 22 The effect of ## p < 0.01, ### p < 0.001 vs DAMGO treatment). Controls, n = 8; DSS, n = 10; DSS+DAMGO, n = 11; DSS+Bcl-2 inhibitor, n = 4; DSS+DAMGO+ Bcl-2 inhibitor, n = 4.
did not have any effect when lOR mRNA levels returned to normal in the delayed phase of colitis. lORs are abundant in the GI tract, where they are localized to enteric neurons and inflammatory cells. [7] [8] [9] 45 As inflammatory cells are substantially increased in acute inflammation, it is reasonable to suggest that they account for most of the upregulation of lOR mRNA and that lORs on these cells mediate DAMGO beneficial effects on inflammation, though an involvement of lORs expressed by enteric neurons cannot be ruled out on the basis of our data. Our hypothesis that the increased expression of lOR mRNA is primarily due to the increased number of inflammatory cells is supported by data showing increased number of lamina propria mononuclear cells immunoreactive for lOR in specimens of patients with active IBD compared to inactive disease and controls, whereas the density of lOR immunoreactive neurons did not change. 22 Upregulation of endogenous opioids such as b-endorphin and enkephalin, which have high affinities for lOR 46 and are also expressed in immune cells of the gut mucosa, 18, 47 has been reported in experimental colitis and IBD. Indeed, b-endorphin expression is increased during the delayed phase of DSS-induced colitis. 48 Furthermore, enkephalin has been reported to be increased in colonic specimens of patients with active Crohn's and ulcerative colitis, where it correlated with the DAI. 49 Though these data cannot be easily compared because of differences in species and methodology, changes in the expression of the opioid system represent a common factor in intestinal inflammation. Finally, it is tempting to speculate that the lack of effect of increasing doses of DAMGO on the inflammatory response in acute colitis is the result of lOR desensitization, a mechanism that reduces cellular response, which is induced by continuous receptor activation. [50] [51] [52] It should also be pointed out that we could not exclude that DSS affected the efficiency of DAMGO to activate lOR or lOR signaling, though this seems unlikely. The increased expression of NF-kB, an important regulator of immune response, in the acute phase of colitis is consistent with its role in the onset of experimental colitis. 53 As NF-kB potentiates inflammatory response by inducing cytokine production 54 and DAMGO prevented NF-kB upregulation, we can propose that the amelioration of DSS colitis and reduction in cytokine expression induced by lOR activation are mediated by DAMGO-induced suppression of NF-kB. NF-kB has also been reported to modulate lOR expression via production and release of the pro-inflammatory cytokine TNFa, 55 further supporting the concept of bidirectional interactions between the lOR and the immune system. The Bcl-xL upregulation induced by DAMGO in acute colitis supports an antiapoptotic effect of lOR activation, which is reinforced by the concomitant reduction in caspase 3 and 7, indexes of apoptosis, induced by DAMGO. This concept is further supported by the suppression of the inhibitory effect of DAMGO on MPO and NF-kB in acute colitis with a Bcl family inhibitor. These findings are consistent with the reported antiapoptotic properties of lORs in hepatocytes as a mechanism underlying the protective effect of lOR agonists in acute hepatitis in mouse. 23 Bcl-xL is a zinc finger protein of the bcl family involved in cell death regulation, which binds with and sequesters proapoptotic effectors, such as Bax, Raf-1 kinase, or other factors, forming heterodimers that promote cell survival and protect tissue from injury-induced cell death. 27, 28 DAMGO-induced upregulation of Bcl-xL paralleled the suppression of NF-kB expression suggesting that the reduction in the acute inflammatory response is triggered by an interplay between Bcl-xL and NF-kB modulated by lOR activation. The absence of clear symptoms of inflammation 4 weeks following DSS cycle suggests remission, but the presence of significant mucosal damage, cellular infiltration, and cytokine expression is indicative of persistent inflammation. A previous study using the same protocol of one cycle of DSS followed by observation up to 4 weeks, showed increasing levels of immune cell infiltration and levels of cytokines that remained elevated throughout the 4 weeks following the end of DSS reaching higher peaks compared to the acute phase, whereas the histological damage and symptoms decreased, a condition that has been regarded as chronic colitis. 35 We have not analyzed periods in between the end of DSS treatment and the 4 weeks following the induction of colitis, thus we cannot establish whether the lower but significant delayed inflammation detected at 4 weeks represents a transition from acute colitis to remission or a progression toward a chronic inflammation following transient remission. Interestingly, in a previous study using DSS as a model of colitis, the administration of the opioid receptor antagonist, naltrexone reduced the inflammatory response. 56 Naltrexone is a universal opioid antagonist that acts on all three opioid receptors, oOR and kOR in addition to the lORs, which are all expressed by enteric neurons and immune cells, and play a role in modulating the inflammatory responses. 9, 17, 57 However, unlike lORs that are immunosuppressive, oORs are likely to be pro-inflammatory. 17 Furthermore, naltrexone passes the blood-brain barrier thus acting both peripherally and centrally. 58 By contrast, DAMGO, which was used in our and previous studies, 20, 24 is a selective lOR agonist that predominantly acts on peripheral lORs because it does not pass the brain-blood barrier. These observations reconcile the apparent discrepancies reported by these studies and raise the possibility that different components of the opioid system interact in modulating inflammatory processes, which warrants further investigation.
In conclusion, our study shows that peripheral lOR activation ameliorates the acute, but not the delayed phase, of DSS-induced colitis. This effect is likely to be dependent on Bcl-xL activation and NF-kB suppression, thus resulting in reduction in pro-inflammatory cytokines and inflammatory response. Our findings support previous observations suggesting that activation of lOR could be explored as a therapeutic target for acute inflammation, 20, 22 but the lack of effect during the delayed phase of colitis does not support a role of lOR agonists in maintaining remission.
